DAPTOMYCIN | A206005 | XELLIA PHARMACEUTICALS APS
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2016-02-10 | Terminated 2016-03-11 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$21.85
per ea
Lowest NADAC/Unit
$21.85
per ea
Brand NDCs
0
Generic NDCs
5
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70594003401DAPTOMYCIN 500 MG VIAL | $21.85 | EA | Generic | — | 2026-06-17 |
| 70594003402DAPTOMYCIN 500 MG VIAL | $21.85 | EA | Generic | — | 2026-06-17 |
| 72572010201DAPTOMYCIN 500 MG VIAL | $21.85 | EA | Generic | — | 2026-06-17 |
| 00143944401DAPTOMYCIN 500 MG VIAL | $21.85 | EA | Generic | — | 2026-06-17 |
| 00143946501DAPTOMYCIN 500 MG VIAL | $21.85 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.